# Remus Pharmaceuticals share price today (Remus Pharmaceuticals Ltd, NSE: REMUS)

> Remus Pharmaceuticals share price today: ₹845.65 at the NSE close on 3 November 2026, up 17.4% in a year. Remus Pharmaceuticals (NSE: REMUS) is worth ₹997 crore, trades at a P/E of 41.3 and has closed between ₹612.75 and ₹1,002.00 over the past 52 weeks. > Remus Pharmaceuticals Ltd's results are improving, while its P/E is near the low end of its own history over 3.4 years, higher than only 28% of past readings. REMUS · Pharma - Others · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹845.65 (+17.4% in a year)
- P/E: 41.3× (lower than 72% of the last 3.4 years)
- Revenue (Mar 2026): ₹47.0 Cr (+14.6% on a year ago)
- Profit (Mar 2026): ₹13.0 Cr (+18.2% on a year ago)
- Operating margin: 32.0% (−4.0 points on a year ago)
- ROCE: 12%, FY26

Biggest thing to watch: the price has already been rising for 12 weeks, so timing is the risk more than the business. ## What is the Remus Pharmaceuticals share price today? Remus Pharmaceuticals Ltd's share price was ₹845.65 at the close on 3 November 2026. It has been rising for 12 weeks. That is 3.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹613 and ₹1,002, and at that close it sat 60% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 15 weeks in a row. Over the last 3.4 years the share price moved +210% while the NIFTY 500 moved +37%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Remus Pharmaceuticals this quarter? Three changes stood out: revenue up on a year earlier for 7 quarters in a row (every quarter we can compare), profit up on a year earlier for 7 quarters in a row (every quarter we can compare) and highest quarterly profit in 9 quarters. 1. Revenue up on a year earlier for 7 quarters in a row (every quarter we can compare) In the March 2026 quarter revenue was ₹47 crore, +14.6% on a year earlier. Why: Revenue rose because selling directly to consumers became a much bigger part of the business, up from 4% to 14-15% of sales. Next results: check whether early FY27 sales confirm the direct-to-consumer business is growing toward 30% of revenue. From the earnings call on 21 May 2026. 2. Profit up on a year earlier for 7 quarters in a row (every quarter we can compare) In the March 2026 quarter profit was ₹13 crore, +18.2% on a year earlier. Why: Profit rose because revenue grew and the company kept the share of sales left after product costs at 55-60% on its core finished medicines. Next results: check whether the group keeps more of each sale after day-to-day costs as direct-to-consumer sales reach 30% of revenue. From the earnings call on 21 May 2026. 3. Highest quarterly profit in 9 quarters Profit of ₹13 crore in the March 2026 quarter is the highest of the last 9 quarters. Why: Profit reached its highest in nine quarters because revenue grew and the company held the share of sales left after product costs at 55-60% on its core finished medicines. From the earnings call on 21 May 2026. ## What are Remus Pharmaceuticals' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Remus Pharmaceuticals reported revenue of ₹47.0 crore, up 14.6% from ₹41.0 crore a year earlier, and a profit of ₹13.0 crore, up 18.2% from ₹11.0 crore. ### Remus Pharmaceuticals results: January to March 2026 against a year earlier

| Measure | January to March 2026 | January to March 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹47.0 crore | ₹41.0 crore | +14.6% |
| Profit | ₹13.0 crore | ₹11.0 crore | +18.2% |
| Earnings per share | ₹10.76 | ₹9.08 | +18.5% |
| Operating margin | 32.0% | 36.0% | −4.0 points |

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. Remus Pharmaceuticals' management discussed these results on a call held on 21 May 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.)

## What is the Remus Pharmaceuticals share price history? Remus Pharmaceuticals closed at ₹845.65 on 3 November 2026, up 17.4% from ₹720.05 a year earlier (31 October 2025) and up 18.5% over three years. Its highest weekly close since June 2023 was ₹1,362.28 on 11 October 2024. ### Remus Pharmaceuticals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹880.60 | −4.0% |
| 1 month ago · 1 Oct 2026 | ₹861.85 | −1.9% |
| 6 months ago · 30 Apr 2026 | ₹685.30 | +23.4% |
| 1 year ago · 31 Oct 2025 | ₹720.05 | +17.4% |
| 3 years ago · 3 Nov 2023 | ₹713.38 | +18.5% |
| Earliest and lowest weekly close in our records · 2 Jun 2023 | ₹272.98 | +209.8% |
| Highest weekly close since June 2023 · 11 Oct 2024 | ₹1,362.28 | −37.9% |
| 52-week high (weekly close) · 16 Oct 2026 | ₹1,002.00 | −15.6% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹612.75 | +38.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (186 weekly closes from 2 June 2023 to 3 November 2026.)

## What is the latest news on Remus Pharmaceuticals? 3 Nov 2026: Remus Pharmaceuticals closed at ₹845.65, down 4.0% on the week and down 1.9% on the month. Our read, 22 Aug 2026: Remus is shifting from a low-margin B2B distributor to a branded B2C pharma company across 40+ emerging markets, if B2C reaches 30% of revenue in FY27, consolidated margins recover and earnings could double from current levels. ### Earlier

- 21 May 2026: Remus Pharmaceuticals held its results call for January to March 2026. Management guided: B2C goal: reach at least 30% of total revenue in FY27; growth drivers include 26 product launches in Bolivia within 2-3 months and 126 trademarks registered in FY26. - Results for January to March 2026: Revenue up 14.6% and profit up 18.2% on a year earlier. ### Our read of the business

Remus grew its consolidated revenue 34x from FY22 to FY26 by acquiring SP Global (US distribution) and building a branded presence across Latin America, Middle East, and Asia. The US distribution unit drags consolidated operating margin to 7%, masking 55-60% gross margins in the core branded formulations business. The case rests on B2C branded revenue scaling from 14-15% to 30% of the total mix, which management expects by FY27, a goal they missed once before (guided 18-20%, achieved 14-15%). Latest quarter: Revenue 453 Cr (30% on a year earlier from 348 Cr), profit 25 Cr; B2C missed 18-20% goal at 14-15%; GLP-1 filing launched. (Our read after the latest results, written 22 August 2026.)

## What dividend does Remus Pharmaceuticals pay? The NSE corporate-actions record has no dividend for Remus Pharmaceuticals since its first NSE close in our records (2 June 2023), so this page cannot show amounts per share. Yes. Remus Pharmaceuticals Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 7 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Remus Pharmaceuticals management say on the latest results call? On the call for January to March 2026, held on 21 May 2026, Remus Pharmaceuticals' management guided: B2C goal: reach at least 30% of total revenue in FY27; growth drivers include 26 product launches in Bolivia within 2-3 months and 126 trademarks registered in FY26. > “We are looking at at least 30% for B2C in FY27, given current portfolio and expected approvals; we expect B2C to double from its current levels”
> Arpit Shah, on the call for January to March 2026

### What management guided

- B2C will double from FY26 run-rate (14-15%) in FY27. - B2B segment to grow 25-30% top-line in FY27. - Peru market will receive 60 product filings within 3 months of DIGEMID audit clearance with commercialization expected within FY27. - Semaglutide to launch in 3-4 non-patented emerging markets in FY27 (filings currently completed); patent expiry mapping in progress for 2026-2029 protected markets with strategic filing preparation underway for first-mover positioning. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/53620-21-May-2026.pdf). (From the call for January to March 2026, 21 May 2026.)

## What could change the Remus Pharmaceuticals story? What are the risks? If B2C contribution in H1 FY27 results (covering April-September 2026) remains below 18% of consolidated revenue, the goal Remus already missed in FY26, the core thesis is breaking: either the Bolivia launches did not execute as guided, or the structural mix shift is slower than the business model implies. A second B2C miss combined with consolidated operating margin staying flat at 7% would mean SP Global is a permanent drag rather than a temporary mix depressant, and the normalized-margin recovery path evaporates. ### Each change stops working if

- : Geopolitical instability (sanctions, forex controls, Ministry of Health delays) prevents prescription renewals or supply from reaching patients, the Bolivia/Venezuela/Ecuador exposure is the tail risk. - : Patent office in the planned non-patented markets extends exclusivity for Semaglutide beyond 2026, or a faster-moving competitor captures the first-to-file slot in key markets. - : A critical CMO partner loses regulatory accreditation for a key product, or the business model requires owned manufacturing to compete in a goal market (e.g., some African markets prefer local-manufactured product). ### The main risks

- : B2C execution risk: management already missed the FY26 goal by 4 percentage points (guided 18-20%, delivered 14-15%). The FY27 goal of 30% is more ambitious from a lower base, and depends on Ministry of Health approvals outside management control. ✓ fact
- : SP Global (US distribution subsidiary) is a permanent margin drag: it operates at near-zero gross margins and dilutes consolidated operating margin to 7%, making it difficult to read underlying business health from reported P&L. ✓ fact
- : Geopolitical risk in Latin America: Bolivia, Venezuela, and Ecuador are high-volatility political environments where forex controls, sanctions, or Ministry of Health delays can halt product launches with no advance warning. ✓ fact
- : Operating cash flow/profit of 0.27 over 3 years raises a caution flag that requires monitoring: while the wc model recognizes pharma launch stocking, the cash-conversion-cycle expansion (CCC: -48 days to +58 days) is a structural shift, not noise. ✓ fact

(Our read after the latest results, written 22 August 2026.)

## What to watch in Remus Pharmaceuticals' next results? When Remus Pharmaceuticals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: Bolivia B2C launch execution - monitor 26 planned products launching within next 2-3 months; track April to June 2026 revenue contribution to confirm B2C re-acceleration narrative and progress toward 30% revenue goal. - What to check (from the call)
- Bolivia B2C launch execution - monitor 26 planned products launching within next 2-3 months; track April to June 2026 revenue contribution to confirm B2C re-acceleration narrative and progress toward 30% revenue goal. - Peru DIGEMID approval velocity - monitor filing-to-approval timelines for 60 planned product filings to assess FY27 commercialization achievement as guided by management. - Semaglutide revenue emergence - track first revenues from 3-4 non-patented emerging markets in H1 FY27 to validate GLP-1 segment launch execution and new therapeutic area expansion capability. - B2C contribution trajectory - monitor whether B2C contribution approaches 18-20% run-rate in early FY27 (from 14-15%) and consolidated operating margin stabilizes vs H2 FY26 reflecting subsidiary operational leverage improvements. ## Which stock lists is Remus Pharmaceuticals on? Remus Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 979.4438845082113](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 979.4438845082113](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Remus Pharmaceuticals profitable? Remus Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Mar 2026 quarter, +18.2% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹25.0 Cr. Over 6 years profit has grown 71.0% a year on average. That is 27.7% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. Why profit moved: revenue changed +14.6% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +21.6% and revenue +20.8%. Profit and revenue are moving at about the same pace. ## How much revenue does Remus Pharmaceuticals make, and is it growing? Remus Pharmaceuticals Ltd reported ₹47.0 Cr of revenue in the Mar 2026 quarter, +14.6% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 6 years it has grown 40.9% a year on average. The last full year, FY26, came in at ₹94.0 Cr. Why this happened. Bolivia subsidiary launched CNS products in H2 FY26 with a focus on life-term prescription categories. Chronic-therapy products in developing markets tend to build annuity-like demand once regulatory approval is obtained and physician adoption follows. The 6-month minimum inventory buffer per country Remus maintains ensures supply continuity, which is the critical retention factor in emerging markets where supply disruption destroys brand loyalty. The advance-payment model (zero collection problems to date per management) further reduces default risk in a high-volatility currency environment. FY26 revenue was ₹94.0 Cr, +19.0% on the year before. Recent pace: the last four quarters grew +20.8% on average, against 40.9% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every ₹100 of sales does Remus Pharmaceuticals keep? Remus Pharmaceuticals Ltd's operating margin was 32.0% in the Mar 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Over the last four quarters it has moved −1.0 percentage points. Across 7 years it has been between 3.3% and 33.0%. The latest quarter is within that range. Why this happened. Remus tracks the value-chain-climb pattern: a company moving from low-value B2B distribution to high-value branded consumer pharma. B2C contribution moved from 4% (FY25) to 14-15% (FY26), and management is aiming for 30% by FY27. At 30% B2C, the consolidated gross margin should structurally recover from 13-14% toward 25-30%, even with SP Global still in the mix. Bolivia (26 product launches planned within 2-3 months of the May 2026 call) and Peru (60 filings post-DIGEMID audit clearance in February 2026) are the near-term execution tests. Why the margin moved: operating margin changed −1.7 percentage points on the year while gross margin changed −2.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Remus Pharmaceuticals' profit turning into cash? Over the last 3 years, 71% of Remus Pharmaceuticals Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹22.0 Cr of operating cash against ₹25.0 Cr of profit. After ₹3.0 Cr of spending on assets, ₹19.0 Cr was left over as free cash. Why this happened. Fixed assets are only 18 Cr for a company with 854 Cr annual revenue, a capital turns ratio of over 47x. This asset-light structure (all manufacturing outsourced to 34 CMO partners) means incremental revenue from new product launches in new markets flows through with very low incremental capex. The constraint on growth is not capital but regulatory and commercial execution speed. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 71% of profit came in as cash: the cash cycle got 113 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 113 days longer. The next section looks at where the cash is stuck. ## Where does Remus Pharmaceuticals' cash go? Remus Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 57 days in FY26, up from −56 days in FY21. It spent ₹10.0 Cr on assets over the last 3 years. Customers take 92 days to pay, and stock sits for 25 days on average. At FY26 sales of ₹94.0 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹15.0 Cr is tied up in the business at any time. FY26: customers took 92 days to pay and stock sat for 25 days, about 0.8 months of sales sitting as stock, for a full cycle of 57 days, longer than FY21's −56. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 25 days. Customers pay about 92 days after that. Suppliers are paid at 60 days. Together that makes the 57-day cycle. Spending on assets: ₹10.0 Cr over the last 3 years, against ₹6.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Remus Pharmaceuticals' P/E ratio, and how does it compare with its own history? Remus Pharmaceuticals Ltd's P/E is 41.3×, near the low end of its own history: it has been lower only 28% of the time. Its usual P/E (the middle reading) is 63.5×, over 3.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +24.4% while the price moved +17.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +5.8% a year; about +40.8% a year came from earnings growth and about −35.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 26% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the Remus Pharmaceuticals share price assume? Worked out from its price on 25 August 2026, Remus Pharmaceuticals Ltd's share price assumed profit growth of about 4.7% a year. Over the past 6 years its profit actually grew 71.0% a year. Today its P/E is 41.3×, lower than 72% of its own last 3.4 years. This is a one-day reading, taken on 25 August 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Remus Pharmaceuticals business getting better or worse? Remus Pharmaceuticals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Remus Pharmaceuticals story, and has it been checked? Remus Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file. Our read, 22 August 2026. Remus is shifting from a low-margin B2B distributor to a branded B2C pharma company across 40+ emerging markets, if B2C reaches 30% of revenue in FY27, consolidated margins recover and earnings could double from current levels. What is proven. Remus is shifting from a low-margin B2B distributor to a branded B2C pharma company across 40+ emerging markets, if B2C reaches 30% of revenue in FY27, consolidated margins recover and earnings could double from current levels. What would change our mind. If B2C contribution in H1 FY27 results (covering April-September 2026) remains below 18% of consolidated revenue, the goal Remus already missed in FY26, the core thesis is breaking: either the Bolivia launches did not execute as guided, or the structural mix shift is slower than the business model implies. A second B2C miss combined with consolidated OPM staying flat at 7% would mean SP Global is a permanent drag rather than a temporary mix depressant, and the normalized-margin recovery…

What the company does. Remus grew its consolidated revenue 34x from FY22 to FY26 by acquiring SP Global (US distribution) and building a branded presence across Latin America, Middle East, and Asia. The US distribution unit drags consolidated OPM to 7%, masking 55-60% gross margins in the core branded formulations business. The case rests on B2C branded revenue scaling from 14-15% to 30% of the total mix, which management expects by FY27, a goal they missed once before (guided 18-20%, achieved 14-15%). What the surface reading misses. The short history and the structural business model change mean the percentile is informative but not as conclusive as a 10-year series would be. What the surface reading misses. This is the best kind of compression: the business is getting lower through earnings growth, not through price collapse alone. Sources: our stock research file (22 August 2026) · quarterly results through Mar 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## How much does Remus Pharmaceuticals earn on its capital? Remus Pharmaceuticals Ltd earned a ROCE of 12% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 26.6% net margin and 0.25× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 26.6% net margin × 0.25× asset turnover × 1.17× leverage (assets divided by equity) ≈ 7.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 26% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Remus Pharmaceuticals have too much debt? Remus Pharmaceuticals Ltd had ₹6.0 Cr of borrowings against ₹326 Cr of equity in FY26, so its debt is 0.02× its equity. Its operating profit is 30 times its interest bill. Over 5 years borrowings went from ₹0.0 Cr to ₹6.0 Cr. Over the last 3 of those years it spent ₹10.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 26% on reported income across 6 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Remus Pharmaceuticals shareholding pattern? Foreign institutions raised their stake in Remus Pharmaceuticals Ltd by 2.7 percentage points over 7 quarters, the biggest change among its owners. Foreign institutions now own 5.1% of the company. Promoters moved +1.3 points over the same period, to 71.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +2.7 points over 7 quarters, to 5.1%; Promoters: +1.3 points over 7 quarters, to 71.0%; Domestic institutions: −0.3 points over 7 quarters, to 0.4%. Why the owners changed: foreign institutions drove it (+2.7 points), together with promoters (+1.3 points). They raised their stake step by step. ## How far is Remus Pharmaceuticals from balance-sheet trouble? For Remus Pharmaceuticals Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Remus Pharmaceuticals rank in its industry? 54.8 out of 100, rank 4 of 10 in Pharma - Others, with 54% of the evidence available. Remus Pharmaceuticals Ltd scores 54.8 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 4. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 17.5 + 13.3 + 11.2 + 12.8 = 54.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Remus Pharmaceuticals compared with? Remus Pharmaceuticals ranks 4 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 54.8 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. Remus Pharmaceuticals Ltd this page REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Remus Pharmaceuticals in size? Remus Pharmaceuticals is the 8th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Panacea Biotec, Syncom Formulations (India), JOJO and TTK Healthcare. Just below it: Madhuveer Com 18 Network and Jenburkt Pharmaceuticals. ### Pharma - Others companies close in size

1. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
2. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
3. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
4. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore
5. Remus Pharmaceuticals Ltd ₹994 crore
6. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) ₹581 crore
7. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) ₹498 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Sai Silks (Kalamandir) Ltd](https://www.sectoralpha.in/stocks/sai-silks-kalamandirltd) ₹996 crore · Textiles - Readymade Apparel
2. [Century Enka Ltd](https://www.sectoralpha.in/stocks/century-enka-ltd) ₹995 crore · Textiles - Manmade Fibre - PFY/PSF
3. Remus Pharmaceuticals Ltd ₹994 crore
4. [Saraswati Commercial (India) Ltd](https://www.sectoralpha.in/stocks/saraswati-commercial-indialtd) ₹991 crore · Finance & Investments - Others
5. [FlySBS Aviation Ltd](https://www.sectoralpha.in/stocks/flysbs-aviation-ltd) ₹989 crore · Transport - Airlines

## What else do people ask about Remus Pharmaceuticals? ### What is Remus Pharmaceuticals's share price today? Remus Pharmaceuticals Ltd's share price is ₹845.65, +17.4% over the past year. The whole company is worth ₹997 Cr on the market. In the last 52 weeks it traded between ₹613 to ₹1,002; today it is 60% of the way up from the low, 3.0% above its 200-day average (as of 3 November 2026). ### What were Remus Pharmaceuticals's latest quarterly results? Remus Pharmaceuticals Ltd reported revenue of ₹47.0 Cr and net profit of ₹13.0 Cr for the Mar 2026 quarter. Revenue rose 14.6% and profit rose 18.2% compared with a year earlier. Earnings per share were ₹10.76. The operating margin was 32.0%, 4.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Remus Pharmaceuticals's market cap? Remus Pharmaceuticals Ltd's market capitalisation is ₹997 Cr at a share price of ₹845.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Remus Pharmaceuticals performing? Remus Pharmaceuticals Ltd's share price has been rising for 12 weeks. In its latest quarter, revenue rose 14.6% and profit rose 18.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 15 weeks running (as of 3 November 2026). ### Will Remus Pharmaceuticals's share price go up? This page does not forecast Remus Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹845.65, and it has been rising for 12 weeks. Its P/E of 41.3× is higher than 28% of its own last 3 years (as of 3 November 2026). ### Who owns Remus Pharmaceuticals? Promoters own 71.0% of Remus Pharmaceuticals Ltd, foreign institutions 5.1%, domestic institutions 0.4% and the public 23.5% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 2.7 percentage points over 7 quarters (as of 3 November 2026). ### Where is Remus Pharmaceuticals in its business cycle? Remus Pharmaceuticals Ltd's FY26 operating margin was 32.0%, against a 7-year range of 3.3% to 33.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 32.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Remus Pharmaceuticals story? Biggest thing to watch: the price has already been rising for 12 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Remus Pharmaceuticals a stock worth studying right now? What the numbers show: Remus Pharmaceuticals Ltd's results are improving, while its P/E is near the low end of its own history over 3.4 years, higher than only 28% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Remus Pharmaceuticals share price forecast for 2026? What management itself guided: B2C goal: reach at least 30% of total revenue in FY27; growth drivers include 26 product launches in Bolivia within 2-3 months and 126 trademarks registered in FY26. What would change the story: If B2C contribution in H1 FY27 results (covering April-September 2026) remains below 18% of consolidated revenue, the goal Remus already missed in FY26, the core thesis is breaking: either the Bolivia launches did not execute as guided, or the structural mix shift is slower than the business model implies. A second B2C miss combined with consolidated operating margin staying flat at 7% would mean SP Global is a permanent drag rather than a temporary mix depressant, and the normalized-margin recovery path evaporates. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.